Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in

  News Archive

Chi-Med Initiates Sulfatinib Phase II Clinical Trial in Thyroid Cancer
Thursday, March 03, 2016
Company has initiated an open-label Phase II clinical trial to evaluate the efficacy and safety of sulfatinib (HMPL-012) in patients with differentiated thyroid cancer (“DTC”) or medullary thyroid cancer (“MTC”).

Crossing a Barrier in the Study of Neurological Disease
Wednesday, March 02, 2016
A human blood-brain barrier-on-a-chip device developed at the Wyss Institute offers new ways of studying drug delivery and neurological disease in vitro.

Biomarker Identifies Eye Cancer Patients at High Risk for Metastasis
Wednesday, March 02, 2016
A study by J. William Harbour, M.D., Associate Director for Basic Research and leader of the Eye Cancer Site Disease Group at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and colleagues details the discovery of a biomarker that puts patients at a higher risk for metastasis of uveal melanoma.

SomaLogic Raises up to $60.5M
Wednesday, March 02, 2016
SomaLogic, Inc., and Visium Healthcare Partners, LP has announced that SomaLogic will receive up to $60.5 million through a combination of debt and equity financing from Visium.

Promising Model for Hantavirus Drug Design
Tuesday, March 01, 2016
X-ray crystallography provides drug template against disease transmitted by small rodents.

NanoString, Merck Expand Collaboration
Tuesday, March 01, 2016
NanoString eligible to receive up to $24 million for technology access and near-term milestones, plus development funding and undisclosed downstream payments.

Oral Bacteria and Esophageal Cancer Linked
Monday, February 29, 2016
Findings represent the first direct evidence that P. gingivalis could be a risk factor for esophageal cancer.

Introducing PeptiMimesis
Monday, February 29, 2016
The company is launching its unique platform to generate transmembrane peptides with the ability to disrupt dimerization of target receptors.

Ubiquigent Strengthens Team to Deliver Cutting Edge Drug Discovery Services
Thursday, February 25, 2016
Ubiquigent has announced that it has significantly enhanced its drug discovery service capabilities by strengthening its commercial and chemistry teams to deliver an even more comprehensive range of services to the global life science research community.

<< 9 10 11 12 13 14 15 >>
Showing Results 111 - 120 of 4197

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos